Trial reportDrug design, development and therapy2026
A Comparison of Tegileridine Fumarate versus Sufentanil on the Quality of Postoperative Recovery After Laparoscopic Sleeve Gastrectomy: A Preliminary Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Laparoscopic sleeve gastrectomy (LSG) is associated with substantial postoperative pain and a high rate of postoperative nausea and vomiting. Tegileridine fumarate, a biased µ-opioid receptor agonist, may offer effective analgesia with fewer adverse effects than conventional opioids. This study compared the impact of tegileridine versus sufentanil analgesia on postoperative recovery quality in obese patients. Methods: Seventy-two patients were randomly assigned to either the tegileridine group (group T, n = 36) or the sufentanil group (group S, n = 36). The primary outcome was the Quality of Recovery-15 (QoR-15) score at 24 h postoperatively. Secondary outcomes included: the visual analogue scale (VAS), time to first rescue analgesia, rescue analgesia and antiemetic use, cumulative opioid consumption, incidence of adverse events, and levels of C-reactive protein (CRP) and interleukin-6 (IL-6). Results: The median (IQR) total QoR-15 score of 105.5 (103-120.8) was higher (p < 0.0001) in the group T compared with the score of 100.5 (93.5-104) in the group S. Group T demonstrated superior early postoperative analgesia, with lower VAS scores at rest (3.61 ± 0.57 vs. 3.91 ± 0.61, P = 0.033) and during movement (4.86 ±0.76 vs. 5.23 ±0.72, P = 0.039). The time to first rescue analgesia was longer in group T compared with group S [38 (32.25-43.75) minutes vs. 21 (17.25-30) minutes, P < 0.001]. Group T had a lower incidence of nausea (36% vs. 23%, P < 0.05) and vomiting (11% vs. 33%, P < 0.05). Rescue analgesic demand, PCIA use and CRP or IL-6 levels at any measured time point showed no significant difference. Conclusion: In patients undergoing LSG, tegileridine demonstrated a modest improvement in recovery quality, comparable analgesia, and significantly fewer opioid-related adverse events versus sufentanil.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.